Cargando…

Tocilizumab for the treatment of systemic onset JIA: a single centre experience from India

Detalles Bibliográficos
Autores principales:	Sawhney, Sujata, Aggarwal, Manjari
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3403057/ http://dx.doi.org/10.1186/1546-0096-10-S1-A49

Ejemplares similares

The efficacy and safety of Tocilizumab in adults with refractory systemic onset JIA
por: Deslypere, G, et al.
Publicado: (2011)

Outcome of repeat dosing of sJIA patients with tocilizumab in one UK centre
por: Livermore, P, et al.
Publicado: (2008)

PReS-FINAL-2038: Clinical efficacy and tolerability of tocilizumab in patients with persistant systemic JIA
por: Mihailova, D, et al.
Publicado: (2013)

PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients
por: Lu, P, et al.
Publicado: (2013)

Tocilizumab (TCZ) may be an effective treatment for poly-juvenile idiopathic arthritis (pJIA) as for rheumatoid arthritis (RA)
por: Yamaguchi, Ken-ichi, et al.
Publicado: (2012)

Tocilizumab in JIA patients who have inadequate response to anti-tumour necrosis factor therapy
por: Russo, R, et al.
Publicado: (2011)

PReS-FINAL-2057: Systemic onset JIA with coronary artery dilatation
por: Aktay Ayaz, N, et al.
Publicado: (2013)

MEFV mutations in systemic JIA
por: Aktay Ayaz, N, et al.
Publicado: (2008)

PReS-FINAL-2139: Tapering and withdrawal of tocilizumab in patients with systemic JIA in inactive disease: results from an alternative dosing regimen in the tender study
por: De Benedetti, F, et al.
Publicado: (2013)

Safety and efficacy of tocilizumab treatment in children with systemic onset of juvenile idiopathic arthritis
por: Alexeeva, E, et al.
Publicado: (2011)

Time of onset of iridocyclitis (IC) in children with juvenile idiopathic arthritis (JIA)
por: Verazza, S, et al.
Publicado: (2008)

Systemic onset Juvenile Idiopathic Arthritis (SoJIA): a monocentric study of 114 patients
por: Melki, I, et al.
Publicado: (2011)

Determing an “autoimmune” phenotype in systemic JIA
por: Fischer, N, et al.
Publicado: (2011)

Tocilizumab in the treatment of systemic-onset juvenile idiopathic arthritis – single-centre experience
por: Roszkiewicz, Justyna, et al.
Publicado: (2018)

Adverse events of methotrexate treatment in JIA
por: in ‘t Veld, J, et al.
Publicado: (2011)

Evaluation of the JIA treatment with adalimumab in ukraine
por: Ponochevna, Elena, et al.
Publicado: (2014)

Juvenile idiopathic arthritis (JIA) in two tertiary centres in the Western Cape, South Africa
por: Weakley, Kate, et al.
Publicado: (2011)

Demographic, clinical and treatment characteristics of the carra registry systemic JIA cohort
por: Janow, Ginger, et al.
Publicado: (2014)

Factors impacting referral of JIA patients to a tertiary level pediatric rheumatology center in North India: a retrospective cohort study
por: Agarwal, Manjari, et al.
Publicado: (2020)

Neuroblastoma versus systemic JIA – a diagnostic dilemma
por: Scalzi, Lisabeth, et al.
Publicado: (2012)

The use of tocilizumab in a child with systemic onset juvenile idiopathic arthritis and ganglioneuroblastoma
por: Goran, Ristic, et al.
Publicado: (2011)

Efficacy and safety of tocilizumab in european children with systemic onset juvenile idiopathic arthritis
por: Nemiche, O, et al.
Publicado: (2011)

Mesenchymal stem cells and JIA
por: Swart, JF, et al.
Publicado: (2011)

The swedish paediatric JIA-registry
por: Magnusson, Bo
Publicado: (2014)

Puberty and disease activity in JIA
por: Van Pelt, Philomine, et al.
Publicado: (2014)

Clinical classification of JIA in Albania
por: Vula, Aurel, et al.
Publicado: (2014)

2.1 Long-term safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis (JIA)
por: Yokota, S, et al.
Publicado: (2008)

Are genetic variants of Caspase-1 and Cryopyrin associated with systemic JIA?
por: Stock, CJ, et al.
Publicado: (2008)

PReS-FINAL-2254: Is it systemic JIA or post infectious illness?
por: Guddeti, P, et al.
Publicado: (2013)

The response to hepatitis a vaccine in children with JIA on immunosuppresive treatment
por: Maritsi, Despoina, et al.
Publicado: (2014)

Safety and efficacy of biological therapy with TNF-inhibitors and non TNF-inhibitors in a cohort of young adults affected by juvenile idiopathic arthritis (JIA): data from a single centre experience
por: Lorenzo, Ceri, et al.
Publicado: (2011)

Effect of ANA positivity on clinical picture of the JIA: should ANA positive JIA be classified as a different group?
por: Polat, Adem, et al.
Publicado: (2011)

Ocular threat in juvenile idiopathic arthritis (JIA)
por: Marvillet, I, et al.
Publicado: (2008)

Use of internet in adolescents and young adults with JIA
por: Van Pelt, Philomine, et al.
Publicado: (2014)

JIA-like in a boy with Ataxia-telangiectasia
por: Furtado, Filipa, et al.
Publicado: (2014)

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data
por: De Benedetti, Fabrizio, et al.
Publicado: (2012)

Monitoring the efficacy of intraarticular infliximab by musculoskeletal ultrasound and juvenile arthritis disease acitivty score (JADAS) in JIA patients – single center experience
por: Vidovic, Mandica, et al.
Publicado: (2014)

Adalimumab treatment in Juvenile Idiopathic Arthritis (JIA) patients with special focus on Uveitis
por: Joos, R, et al.
Publicado: (2011)

Gene expression in active systemic JIA after anti-IL1 and anti-IL6R treatment
por: Ogilvie, EM, et al.
Publicado: (2008)

An in-depth analysis of young people's experience of their juvenile idiopathic arthritis (JIA) once receiving Etanercept
por: Livermore, P, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_p8g383pjl20tfhkhrp2he7h9c9